<DOC>
	<DOCNO>NCT00004060</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treating patient recurrent , metastatic , unresectable ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Recurrent , Metastatic , Unresectable Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity DX-8951f patient recurrent , metastatic , unresectable ovarian , tubal , peritoneal carcinoma refractory platinum , taxane , topotecan . II . Evaluate quantitative qualitative toxic effect regimen patient . III . Evaluate pharmacokinetics regimen patient . OUTLINE : Patients stratify prior chemotherapy ( minimally pretreated vs heavily pretreated ) . Patients receive intravenous DX-8951f 30 minute daily 5 day . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 37 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent , metastatic , unresectable ovarian , tubal , peritoneal carcinoma refractory platinum , taxane , topotecan Must receive least 1 prior chemotherapy regimen Resistance platinum , taxane , topotecan define follow : Progressive disease chemotherapy OR Relapse within six month complete chemotherapy OR Failure achieve complete response six course chemotherapy No recurrent metastatic disease amenable attempted curative therapy surgery and/or radiotherapy Measurable disease No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No psychiatric disorder mental disability No malignancy within past 5 year , except : Nonmelanomatous skin cancer Carcinoma situ cervix No life threaten illness No history camptothecin derivative allergy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery No concurrent surgery Other : At least 4 week since prior investigational drug No concurrent investigational drug 4 week study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>